GO
| HSI1 | 24,988.04 | -347.91 | 136.73B |
| HSCEI1 | 8,452.52 | -130.22 | 59.78B |
| Back Zoom + Zoom - Block Traded | |
|
2026-03-26 08:27:19 Hengrui Medicine (01276.HK) announced its annual results for the year ended last December, with revenue of RMB31.629 billion, up 13% year-on-year. Net profit was RMB7.711 billion, up 21.7% year-on-year; EPS was RMB1.19. The final dividend is RMB2 per 10 shares. The company attributed the increase in revenue mainly to (1) the growth in sales of innovative drugs; and (2) the increase in licensing income. Sales of innovative drugs and licensing income amounted to RMB19.735 billion, accounting for 62.4% of total revenue during the reporting period. Sales revenue from innovative drugs was RMB16.342 billion, up 26.1% year-on-year, accounting for 51.7% of total revenue and 58.3% of drug sales. The gross profit margin remained stable at 86.2% (compared to 86.2% for the year ended December 31, 2024). The net profit margin increased from 22.6% for the year ended December 31, 2024, to 24.4% for the year ended December 31, 2025, mainly due to the growth in gross profit and improved cost efficiency in sales, general, and administrative expenses. As of now, the company has received approval to market 24 Class 1 innovative drugs in China, building an industry-leading and highly differentiated product matrix. According to the pipeline scale ranking released by Citeline in 2025, the company's self-developed pipeline ranks second globally. During the reporting period, several clinical pipelines made significant progress, and approximately 53 innovative products and indications are expected to be approved in the next three years (2026-2028), continuously realizing innovative value. By the end of 2025, the company was conducting approximately 3,200 post-marketing medical research projects, covering a cumulative total of about 8,000 research centers. During the year, a total of 381 significant research results were published in top global journals, including "The Lancet" and "JAMA", contributing "China's evidence" to global clinical practice. (ca/w)~ AASTOCKS Financial News Website: www.aastocks.com | |